Heather Brianne Dixon, President and Chief Operating Officer of Addus HomeCare Corp (NASDAQ: ADUS), executed a transaction to sell 288 shares of the company's common stock on June 22, 2026. The sale, valued at $27,005, was conducted at a price of $93.77 per share. This transaction was facilitated through a pre-established 10b5-1 trading plan, which was initially adopted on November 6, 2025. The primary purpose of the sale was to satisfy tax obligations arising from the vesting of restricted stock awards granted by Addus HomeCare Corp.
Following this transaction, Ms. Dixon's direct holdings in Addus HomeCare Corp common stock stand at 44,371 shares. The sale occurs while the company's stock trades at $96.09, a level that InvestingPro analysis indicates may suggest the stock is undervalued relative to its fair value. Additionally, Addus HomeCare has been assigned a "GREAT" financial health score of 3.44. The company has demonstrated 19.6% revenue growth over the last twelve months.
Recent corporate developments provide additional context to the insider activity. Addus HomeCare Corporation reported its first-quarter 2026 earnings, revealing a stronger-than-expected earnings per share (EPS) of $1.62, which surpassed analyst forecasts of $1.55. Despite this positive earnings performance, the company's consolidated revenue of $363.6 million, while up 7.7% year-over-year, fell short of consensus expectations of $366.4 million.
Market response to these results included action from Citizens, a financial firm, which lowered its price target on Addus HomeCare shares from $150 to $142, although it maintained a Market Outperform rating. The firm noted that Addus HomeCare trades at 8.5 times its 2026 EBITDA estimate, which is at the lower end of its historical trading range. These developments have led to mixed investor sentiment regarding the company's financial health.
Investors seeking deeper insights into ADUS's valuation and growth prospects can access a comprehensive Pro Research Report, available for this and 1,400+ other US equities.
Key Points:
- Insider Sale Structure: The transaction was executed under a 10b5-1 trading plan adopted in November 2025, specifically to cover tax liabilities from vested restricted stock awards.
- Valuation Context: The stock trades at $96.09, with analysis suggesting undervaluation relative to fair value, supported by a "GREAT" financial health score of 3.44 and significant revenue growth.
- Earnings vs. Revenue Divergence: First-quarter 2026 EPS of $1.62 beat estimates, but revenue of $363.6 million missed consensus, highlighting a disconnect between profitability and top-line growth expectations.
Risks and Uncertainties:
- Analyst Target Adjustment: Citizens lowered its price target from $150 to $142, reflecting caution despite maintaining a positive rating, which may influence market perception.
- Mixed Sentiment Signals: The combination of earnings beats and revenue misses, alongside trading at the lower end of its historical EBITDA range, creates uncertainty about near-term price direction.
Disclaimer: This article is for informational purposes only and does not constitute financial advice. Investors should conduct their own due diligence.